Skip to main content

US Healthcare AI: HHS and FDA Governance Requirements

US healthcare organizations are under pressure to move faster with AI while staying inside rules that were never written as a single “AI law.” HHS, primarily through the Office for Civil Rights, still enforces HIPAA Privacy, Security, and Breach Notification duties when protected health information is involved. FDA oversight enters when software functions move into clinical decision support or software-as-a-medical-device territory based on intended use, claims, and actual workflow effect. That means the real governance question is not whether AI is allowed. It is whether you can prove that a particular AI workflow handled PHI appropriately, stayed inside its clinical role, and left enough evidence for review.

Keeptrusts is useful in that environment because it lets teams govern the route rather than hope that model behavior stays inside policy boundaries on its own. It can reduce or block PHI before a provider call, enforce provider metadata such as retention and training posture, add medical-output disclaimers, escalate higher-risk outputs for human review, and preserve decision evidence through events and exports. That does not remove the need for BAAs, legal review, quality management, or device-regulatory analysis. It does give the organization a much stronger runtime story.

Use this page when​

  • You operate AI in a covered entity, business associate, health-tech vendor, provider group, payer, or digital-health platform.
  • You need to separate HHS privacy and security obligations from FDA oversight questions without splitting your operating model into disconnected tools.
  • You want practical controls for patient-facing, clinician-support, and administrative AI routes.

Primary audience​

  • Primary: healthcare compliance leaders, security engineers, platform teams
  • Secondary: privacy officers, product managers, clinical informatics teams, regulatory affairs

The problem​

Healthcare AI deployments often mix fundamentally different workloads in one route. A patient-message summarizer, a coding assistant, an ambient documentation helper, and a symptom-triage tool may all use the same provider and the same prompt path even though their regulatory posture is not the same. That is risky because the control questions differ.

Administrative workflows are dominated by PHI handling, minimum-necessary use, access control, and auditability. Clinical-support workflows add another layer: even if the system is not making an autonomous diagnosis, the output may look authoritative enough to influence care decisions. FDA issues then become relevant where intended use, product claims, or decision-making role place the software inside device-oriented oversight. Many teams discover that too late, after a helpful assistant starts sounding like a clinical system.

The evidence problem is just as serious. An organization may say it uses redaction, provider review, and human oversight, but reviewers still need to see when those controls actually ran. Without route-level telemetry, it becomes difficult to answer basic questions. Was PHI sent upstream? Was a clinical-looking response escalated? Was the provider posture appropriate for patient data? If the answer depends on tribal knowledge, the operating model is fragile.

The solution​

The best pattern is to classify healthcare AI into lanes before rollout. Start with at least three. One lane for administrative automation, one lane for clinician-support content, and one lane for anything device-adjacent or high-consequence enough that you need stricter review and design discipline.

Keeptrusts supports that structure well. prompt-injection protects the request boundary from hostile instructions hidden in uploaded notes or copied patient messages. hipaa-phi-detector addresses PHI-like identifiers in text. data-routing-policy enforces the provider posture your privacy and procurement teams actually approved for healthcare traffic. healthcare-compliance is an output guard that can block certain diagnosis or prescribing phrases and prepend a medical disclaimer when output looks like advice. human-oversight provides a hard escalation stop when the organization decides a route should support a clinician or reviewer, not bypass them.

For FDA-sensitive workflows, this matters because a governed route helps you preserve the intended role of the software. If a system is supposed to assist documentation or information retrieval, the route should make it difficult for the tool to drift into diagnostic or prescribing behavior. If a workflow is clinical enough that device analysis is unavoidable, the same evidence stream becomes useful in design review, validation, and post-deployment oversight.

Implementation​

Run a tight validation loop before any route is considered production ready.

kt policy lint --file policy-config.yaml
kt policy test --json
kt gateway run --listen 0.0.0.0:41002 --policy-config policy-config.yaml
kt events tail --since 24h --json
kt export-jobs create --since 30d --format json --wait

The command sequence is deliberately simple. Lint the config, run policy scenarios, start the gateway, inspect real decision events, and then generate a review package. That loop should be repeated whenever you change provider posture, PHI handling, or escalation behavior.

Use HIPAA PHI Detector where PHI-like content may appear in requests, and pair it with Healthcare Compliance when model output must stay out of diagnosis or treatment language. Add Human Oversight for routes where a person must remain the final decision maker, and use Data Routing Policy to keep provider selection aligned with privacy and procurement commitments. The most helpful operational references are Secure Healthcare AI and Tutorial: PII Redaction Setup.

Results and impact​

Organizations that adopt lane-based healthcare governance usually see a better separation of duties almost immediately. Administrative assistants become easier to approve because they have one PHI-focused control path. Clinician-support routes become easier to defend because the output guard and escalation logic are explicit. Device-adjacent functions become easier to assess because the route no longer hides behind a generic AI feature label.

The other major benefit is audit and incident readiness. When a privacy, quality, or regulatory reviewer asks what happened in a specific time window, the team can start from decision events and export jobs instead of reconstructing behavior from model logs, ticket comments, and screenshots.

Key takeaways​

  • US healthcare AI governance is shaped by both HHS privacy and security obligations and FDA oversight when intended use crosses into clinical software territory.
  • Administrative and clinical AI workflows should not share the same control assumptions.
  • hipaa-phi-detector, data-routing-policy, healthcare-compliance, and human-oversight answer different parts of the healthcare governance problem.
  • Keeptrusts provides a runtime control boundary and evidence trail, but it does not replace BAAs, quality systems, or device-regulatory review.
  • The safest operating model is to classify routes early and validate them continuously.

Next steps​